A concentrated esmolol formulation is provided that is distinguishable from a diluted form of the concentrated esmolol formulation.
대표청구항▼
1. A colored concentrated esmolol formulation comprising: a) from about 25 to about 1000 mg/ml of esmolol;b) from about 0.005 to about 2 M of a buffering agent; andc) a color additive selected from the group consisting of indocyanine green, phenolpthalein, hemoglobin, cyanocobalamin, patent blue, in
1. A colored concentrated esmolol formulation comprising: a) from about 25 to about 1000 mg/ml of esmolol;b) from about 0.005 to about 2 M of a buffering agent; andc) a color additive selected from the group consisting of indocyanine green, phenolpthalein, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals;wherein the formulation has a pH of from about 3.5 to about 7.0, and wherein the concentrated esmolol formulation has a color which is distinguishable from a dilution of the concentrated esmolol formulation, the dilution having a ratio of about one part concentrate to at least four parts diluent. 2. The formulation of claim 1, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof. 3. The formulation of claim 2, wherein the buffering agent comprises sodium acetate and acetic acid. 4. The formulation of claim 3 further comprising from about 1 to about 60% by volume ethanol and from about 5 to about 60% by volume propylene glycol. 5. The formulation of claim 4 comprising about 26.5% by volume ethanol and 25% by volume propylene glycol. 6. The formulation of claim 1, wherein the coloring agent is cyanocobalamin. 7. The formulation of claim 1 wherein the coloring agent is selected from the group consisting of from about 0.002 to about 0.003 mg/ml of cyanocobalamin, from about 0.0005 to about 0.001 mg/ml of indigo carmine and from about 0.0001 to about 0.0003 mg/ml of patent blue. 8. The formulation of claim 1 comprising: a) about 250 mg/ml esmolol HCl;b) about 17 mg/ml sodium acetate trihydrate;c) about 0.00715 ml/ml glacial acetic acid;d) about 0.265 ml/ml ethanol;e) about 0.25 ml/ml propylene glycol; andf) about 0.0024 mg/ml cyanocobalamin. 9. The formulation of claim 1 comprising: a) about 250 mg/ml esmolol HCl;b) about 17 mg/ml sodium acetate trihydrate;c) about 0.00715 ml/ml glacial acetic acid;d) about 0.265 ml/ml ethanol;e) about 0.25 ml/ml propylene glycol; andf) about 0.0002 mg/ml patent blue. 10. The formulation of claim 1 comprising: a) about 250 mg/ml esmolol HCl;b) about 17 mg/ml sodium acetate trihydrate;c) about 0.00715 ml/ml glacial acetic acid;d) about 0.265 ml/ml ethanol;e) about 0.25 ml/ml propylene glycol; andf) about 0.0008 mg/ml indigo carmine. 11. The colored concentrated esmolol formulation of claim 1, wherein the formulation comprises from about 100 to 300 mg/ml of esmolol. 12. The colored concentrated esmolol formulation of claim 1, wherein the dilution of the concentrated esmolol formulation is substantially colorless or the color of the diluent. 13. A medical product comprising: a) a concentrated esmolol formulation comprising from about 25 to about 1000 mg/ml of esmolol hydrochloride, about 0.005 to about 2 M of a buffering agent and a color additive selected from the group consisting of indocyanine green, phenolpthalein, hemoglobin, cyanocobalamin, patent blue, indigo carmine, vitamin B2 and naturally occurring vitamins and minerals housed in a container, wherein the concentrated esmolol formulation has a color which is distinguishable from a dilution of the concentrated esmolol formulation, the dilution having a ratio of about one part concentrate to at least four parts diluent.b) instructions; andc) a package housing the container and instructions. 14. The medical product of claim 13, wherein the buffering agent comprises at least one of acetate, glutamate, citrate, tartrate, benzoate, lactate, gluconate, phosphate and glycine and conjugate acids thereof. 15. The medical product of claim 14, wherein the buffering agent comprises sodium acetate and acetic acid. 16. The medical product of claim 15 further comprising from about 5to about 60% by volume ethanol and from about 5 to about 60% by volume propylene glycol. 17. The medical product of claim 16 comprising about 26.5% by volume ethanol and 25% by volume propylene glycol. 18. The medical product of claim 13 wherein the color additive is selected from the group consisting of from about 0.002 to about 0.003 mg/ml of cyanocobalamin, from about 0.0005 to about 0.001 mg/ml of indigo carmine and from about 0.0001 to about 0.0003 mg/ml of patent blue. 19. The medical product of claim 13, wherein the formulation comprises: a) about 250 mg/ml esmolol HCl;b) about 17mg/ml sodium acetate trihydrate;c) about 0.00715 ml/ml glacial acetic acid;d) about 0.265 ml/ml ethanol;e) about 0.25 ml/ml propylene glycol; andf) a color additive and amount selected from the group consisting of about 0.0008 mg/ml indigo carmine, about 0.0002 mg/ml patent blue, about 0.0024 mg/ml cyanocobalamin. 20. The medical product of claim 13 wherein the instructions notify that a color additive has been added to the concentrated esmolol formulation. diluent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (173)
Glen John Baird (Macclesfield EN) James Roger (Macclesfield EN), 2,6-Diisopropylphenol as an anaesthetic agent.
Uemura Yahiro (Hirakata JPX) Nagatomo Midori (Takatsuki JPX) Funakoshi Satoshi (Katano JPX) Suyama Tadakazu (Kyoto JPX), Antithrombin preparation and process for the production thereof.
Bagchi Pranab (Webster NY) Scaringe Raymond P. (Rochester NY) Bosch H. William (Bryn Mawr PA), Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers.
Albrechtsen Sten,DKX ; Orup-Jacobsen Lene,DKX ; Hansen Jens,DKX ; Mollgaard Birgitte,DKX, Composition for drug delivery comprising nicotine or a derivative thereof and starch microspheres and method for the ma.
Orsolini Piero (Martigny CHX) Heimgartner Frederic (Martigny CHX), Composition for the sustained and controlled release of medicamentous substances and a process for preparing the same.
Midler ; Jr. Michael (East Brunswick NJ) Paul Edward L. (Chatham Township ; Morris County NJ) Whittington Edwin F. (Linden NJ) Futran Mauricio (Westfield NJ) Liu Paul D. (Concord MA) Hsu Jaanpyng (Co, Crystallization method to improve crystal structure and size.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants.
Anand C. Burman IN; Rama Mukherjee IN; Dhiraj Khattar IN; Mukesh Kumar IN; Honey Bala IN; Rajiv Kumar Shrivastava IN, Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof.
Gallagher Paula M. (Bradford MA) Krukonis Val J. (Lexington MA) Coffey Michael P. (Townsend MA), Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX.
Bong-Jin Cha KR; Jun-Gyo Oh KR; Su-Eon Kim KR, Intraconazole exhibiting an improved solubility, a method of preparing the same and a pharmaceutical composition for oral administration comprising the same.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Woiszwillo James E. ; Brown Larry R. ; Scott Terrence L. ; Di Jie ; Sudhalter Judith ; Blizzard Charles D. ; Riske Frank J., Macromolecular microparticles and methods of production and use.
Tapesh Yadav ; Ming Au ; Bijan Miremadi ; John Freim ; Yuval Avniel ; Roger Dirstine ; John Alexander ; Evan Franke, Materials and products using nanostructured non-stoichiometric substances.
Erhardt Paul W. (Mundelein IL) Borgman Robert J. (Mundelein IL) O\Donnell John P. (Morgantown WV), Method for treatment or prophylaxis of cardiac disorders.
Erhardt Paul W. (Mundelein IL) Borgman Robert J. (Mundelein IL) O\Donnell John P. (Morgantown WV), Method for treatment or prophylaxis of cardiac disorders.
Wretlind ; Karl A. J. ; Ljungberg ; Stellan ; Hakansson ; Ivan ; Ajaxon ; Bengt M., Method of enhancing the administration of pharmalogically active agents.
Bruno Joseph A. (Blue Bell PA) Doty Brian D. (Phoenixville PA) Gustow Evan (Ardmore PA) Illig Kathleen J. (Phoenixville PA) Rajagopalan Nats (Phoenixville PA) Sarpotdar Pramod (Malvern PA), Method of grinding pharmaceutical substances.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of making nanoparticulate X-ray blood pool contrast agents using high molecular weight nonionic surfactants.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Method of preparing nanoparticle compositions containing charged phospholipids to reduce aggregation.
Rossling Georg,DEX ; Albayrak Celal,DEX ; Tack Johannes,DEX ; Schmitz Reinhard,DEX, Method of producing morphologically uniform microcapsules and microcapsules produced by this method.
Liversidge Gary G. (West Chester PA) Phillips Christopher P. (Brandamore PA) Cundy Kenneth C. (Belmont CA), Method to reduce particle size growth during lyophilization.
Subramaniam Bala ; Saim Said ; Rajewski Roger A. ; Stella Valentino, Methods for a particle precipitation and coating using near-critical and supercritical antisolvents.
Soon-Shiong Patrick (Los Angeles CA) Desai Neil P. (Los Angeles CA) Grinstaff Mark W. (Pasadena CA) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champaign IL), Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful th.
Grinstaff Mark W. (Pasadena CA) Soon-Shiong Patrick (Los Angeles CA) Wong Michael (Champagne IL) Sandford Paul A. (Los Angeles CA) Suslick Kenneth S. (Champagne IL) Desai Neil P. (Los Angeles CA), Methods for the preparation of immunostimulating agents for in vivo delivery.
Liversidge Gary G. ; Engers David A. ; Roberts Mary E. ; Ruddy Stephen B. ; Wong Sui-Ming ; Xu Shuqian, Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers.
Liversidge Gary G. ; Engers David A. ; Roberts Mary E. ; Ruddy Stephen B. ; Wong Sui-Ming ; Xu Shuqian, Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors.
Baurain Roger (Wezembeek BEX) Trouet Andre B. L. (Winksele BEX), Microcrystals comprising an active substance having an affinity for phospholipids, and at least one phospholipid, proces.
Bagchi Pranab (Webster NY) Stewart Robert C. (Spencerport NY) McIntire Gregory L. (West Chester PA) Minter John R. (Rochester NY), Microprecipitation of micro-nanoparticulate pharmaceutical agents.
Bagchi Pranab (Webster NY) Karpinski Piotr H. (Fairport NY) McIntire Gregory L. (West Chester PA), Microprecipitation of nanoparticulate pharmaceutical agents.
Bagchi Pranab ; McIntire Gregory L. ; Minter John R., Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmace.
Liversidge Gary G. ; Engers David A. ; Roberts Mary E. ; Ruddy Stephen B. ; Wong Sui-Ming ; Xu Shuqian, Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers.
Domb Abraham J. (Efrat ILX) Gref Ruxandra (Nancy FRX) Minamitake Yoshiharu (Ota JPX) Peracchia Maria T. (Parma ITX) Langer Robert S. (Newton MA), Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Perrier Eric,FRX ; Buffevant Chantal,FRX ; Bonnet Isabelle,FRX ; Levy Marie-Christine,FRX, Particles of cross-linked proteins and polysaccharides with hydroxamic groups for chelating metals and their uses notably in cosmetics.
Levy Marie-Christine (Reims FRX) Edwards-Levy Florence (Reims FRX) Orly Isabelle (Lyons FRX), Particles prepared by transacylation reaction between an esterified polysaccharide and a polyamine, methods of preparati.
Perrier Eric,FRX ; Rey-Goutenoire Sylvie,FRX ; Buffevant Chantal,FRX ; Levy Marie-Christine,FRX ; Pariot Nadine,FRX ; Edwards Florence,FRX ; Andry Marie-Christine,FRX, Particles, especially microparticles or nanoparticles, of crosslinked monosaccharides and oligosaccharides, processes for their preparation and cosmetic, pharmaceutical or food compositions in which .
Samain Daniel (Toulouse FRX) Bec Jean-Louis (Ramonville S. Agne FRX) Cohen Edith (L\Union FRX) Nguyen Frdrique (Toulouse FRX) Peyrot Marianne (Toulouse FRX), Particulate vector useful in particular for the transport of molecules with biological activity and process for its prep.
Escobar Agustin (Aquadilla PR) Wagenknecht Dietmar (Zion IL) Malick Ahmad W. (Edison NJ), Pharmaceutical composition and method of treatment or prophylaxis of cardiac disorders.
Chang Steve H. ; Cromack Keith R. ; Flament-Garcia Mary Jane ; Garapolo Joan ; Loffredo David ; Raghavan Rajagopalan ; Ramsay George M. ; Rice Patrick ; Setesak Jeffrey, Polymethylpentene container for an inhalation anesthetic.
Leclef Brigitte (Brussels BEX) Cerfontaine Patrick (Brussels BEX) Nicolas Jean-Marie (Overijse BEX) Wantier Henri (Dour BEX) Trouet Andr (Winksele Herent BEX), Process for preparing lipid microparticles.
Bosch H. William (Bryn Mawr PA) Marcera Donna M. (Collegeville PA) Mueller Ronald L. (Downingtown PA) Swanson Jon R. (Macungie PA) Mishra Dinesh S. (Harleysville PA), Process for preparing therapeutic compositions containing nanoparticles.
Fessi Curt (Paris FRX) Devissaguet Jean-Philippe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Thies Curt (St. Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Stainmesse Serge (Choisy Le Roi FRX) Fessi Hatem (Paris FRX) Devissaguet Jean-Phillppe (Neuilly S/Seine FRX) Puisieux Francis (Maisons Alfort MO FRX) Theis Curt (Saint Louis MO), Process for the preparation of dispersible colloidal systems of a substance in the form of nanoparticles.
Stainmesse Serge (Choisy le Roi FRX) Fessi Hatem (Paris FRX) Devissaguet Jean-Philippe (Neuilly sur Seine FRX) Puisieux Francis (Maisons-Alfort FRX), Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposome.
Maitra Amarnath,INX ; Ghosh Prashant Kumar,INX ; De Tapas K.,INX ; Sahoo Sanjeeb Kumar,INX, Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles.
Devissaguet Jean-Philippe (Neuilly sur Seine FRX) Fessi Hatem (Paris FRX) Puisieux Francis (Maisons Alfort FRX), Process for the preparaton of dispersible colloidal systems of a substance in the form of nanocapsules.
Weder Hans G. (Saumerstrasse 68 CH-8800 Thalwil CHX) Mtsch Matthias (Zurich CHX), Process for the production of a nanoemulsion of oil particles in an aqueous phase.
Johnston Harold Eugene ; Wardle Robert B., Process of crystallizing 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12,-hexaazatetracyclo [5.5.0.0.5,903,11]- dodecane.
Swanson Jon R. (Macungie PA) Bosch H. William (Bryn Mawr PA) Illig Kathleen J. (Phoenixville PA) Marcera Donna M. (Collegeville PA) Mueller Ronald L. (Downingtown PA), Process of preparing x-ray contrast compositions containing nanoparticles.
Pace Gary W. ; Vachon Michael G.,CAX ; Mishra Awadhesh K.,CAX ; Henrikson Inge B.,NOX ; Krukonis Val, Processes to generate submicron particles of water-insoluble compounds.
Desai Neil P. ; Tao Chunlin ; Yang Andrew ; Louie Leslie ; Zheng Tianli ; Yao Zhiwen ; Soon-Shiong Patrick ; Magdassi Shlomo,ILX, Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof.
Ruddy Stephen B. (Schwenksville PA) Eickhoff W. Mark (Downingtown PA) Liversidge Gary (West Chester PA), Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylen.
Frank Sylvan G. (Columbus OH) Brodin Arne F. (Sodertalje NY SEX) Chen Chih-Ming J. (East Syracuse NY) Shrivastava Ratnesh (Columbus OH), Small particle formation.
Frank Sylvan G. (Columbus OH) Brodin Arne F. (Sodertalje NY SEX) Chen Chih-Ming J. (East Syracuse NY) Panthuvanich Siriporn (Columbus OH), Small particule formation and encapsulation.
Niels P. Ryde ; Stephen B. Ruddy, Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate.
Bissery Marie-Christine,FRX ; Laborie Michel,FRX ; Vacus Joel,FRX ; Verrecchia Thierry,FRX, Stabilized nanoparticles which may be filtered under sterile conditions.
Rosenberg Leonard S. (Lake Villa IL) Black Cheryl (Vernon Hills IL) Speicher Earl R. (Buffalo Grove IL) Wagenknecht Dietmar (Waukegan IL), Stable pharmaceutical composition.
Wong Sui-Ming (Collegeville PA) Newington Ian M. (Hazlemere GB2) Liversidge Elaine M. (West Chester PA) McIntire Gregory L. (West Chester PA) Pitt Alan R. (Sandridge GBX) Shaw Jack M. (Aberdeen MD), Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions.
Liversidge Gary G. (West Chester PA) Conzentino ; Jr. Philip (West Chester PA) Cundy Kenneth C. (Pottstown PA) Sarpotdar Pramod P. (Malvern PA), Surface modified NSAID nanoparticles.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Use of ionic cloud point modifiers to prevent particle aggregation during sterilization.
Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA), Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization.
Hollister Kenneth R. (Chester Springs PA) Ladd David (Wayne PA) McIntire Gregory L. (West Chester PA) Na George C. (Fort Washington PA) Rajagopalan Natarajan (Phoenixville PA) Yuan Barbara O. (Villan, Use of purified surface modifiers to prevent particle aggregation during sterilization.
Liversidge Gary G. (West Chester PA) Cooper Eugene R. (Berwyn PA) Shaw J. Michael (King of Prussia PA) McIntire Gregory L. (West Chester PA), X-ray contrast compositions useful in medical imaging.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.